Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIAMOX vs DICHLORPHENAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
Treatment of elevated intraocular pressure in open-angle glaucoma,Secondary glaucoma,Preoperative reduction of intraocular pressure in acute angle-closure glaucoma,Adjunctive treatment of edema due to congestive heart failure,Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Altitude sickness (acute mountain sickness) prophylaxis and treatment
Treatment of increased intraocular pressure in chronic open-angle glaucoma,Secondary glaucoma,Preoperatively in acute angle-closure glaucoma,Off-label: Treatment of familial periodic paralysis,Off-label: Management of altitude sickness
250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure
25-50 mg orally twice daily.
10-15 hours; prolonged to up to 24+ hours in renal impairment; clinical context: requires twice-daily dosing for continuous effect.
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Metabolized primarily via hydrolysis to acetazolamide (active) and then further to inactive metabolites; minimal hepatic metabolism.
Dichlorphenamide is not extensively metabolized; it is excreted unchanged in urine.
Renal; 70-100% unchanged by tubular secretion and passive reabsorption; p H-dependent; alkaline urine increases elimination.
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
~90% bound, primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
90-95% bound to plasma proteins, primarily albumin.
0.2 L/kg; distributes into total body water; concentrates in red blood cells, kidney, and eye.
0.2-0.3 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Oral: ~100% (well absorbed, but food may delay absorption).
Oral: approximately 80-100% (well absorbed); bioavailability not defined for parenteral routes as not typically given.
GFR 10-50 m L/min: 250 mg every 12 hours; GFR <10 m L/min: avoid use
Cr Cl <50 m L/min: not recommended; Cr Cl 50-80 m L/min: 25 mg once daily; Cr Cl >80 m L/min: no adjustment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: avoid use.
Glaucoma: 8-15 mg/kg/day orally divided every 6-8 hours; Edema: 5 mg/kg IV or IM every 6 hours
Not established; safety and efficacy not determined in children.
Start at lowest dose (250 mg orally every 12 hours); monitor renal function and electrolytes due to increased risk of metabolic acidosis and hypokalemia
Start at 25 mg once daily; monitor renal function and electrolytes.
No FDA black box warning.
None.
May cause metabolic acidosis; use caution in patients with pulmonary obstruction or emphysema.,Sulfonamide derivative; may cause hypersensitivity reactions including Stevens-Johnson syndrome.,Contraindicated in severe hepatic or renal dysfunction; may precipitate hepatic encephalopathy.,Monitor serum electrolytes and blood counts during prolonged therapy.,May impair mental alertness; caution when driving or operating machinery.
Metabolic acidosis: Can occur, especially in patients with renal impairment or electrolyte disturbances.,Hypokalemia: Risk may increase due to bicarbonate loss and metabolic acidosis.,Sulfonamide allergy: Cross-sensitivity possible; caution in patients with history of sulfonamide hypersensitivity.,Renal impairment: Use with caution; may accumulate and worsen acidosis.,Hepatic impairment: Caution due to risk of hepatic encephalopathy.,Drug interactions: May increase effects of other carbonic anhydrase inhibitors, furosemide, and decrease effects of lithium.,Pregnancy: Weigh risks vs benefits; not recommended.,Lactation: Excreted in milk; avoid breastfeeding.
Hypersensitivity to acetazolamide or any sulfonamide,Severe hepatic disease or cirrhosis,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Hyperchloremic acidosis,Adrenal insufficiency
Hypersensitivity to dichlorphenamide or other sulfonamides,Severe renal impairment (e.g., anuria, severe nephropathy),Severe hepatic disease,Hepatic encephalopathy,Hypokalemia (uncorrected),Metabolic acidosis (uncorrected),Adrenal insufficiency,Hyperchloremic acidosis,Pregnancy (relative contraindication),Lactation (relative contraindication)
Avoid high-dose vitamin C (may increase risk of kidney stones). No other significant food interactions.
Avoid high-dose aspirin or salicylates; may increase toxicity. Limit alcohol intake to reduce risk of metabolic acidosis. No specific food restrictions but maintain adequate hydration to prevent renal calculi. Avoid cranberry juice if prone to kidney stones.
Diamox (acetazolamide) is a carbonic anhydrase inhibitor. Animal studies show teratogenic effects (limb malformations) at high doses, but human data limited. First trimester exposure may be associated with increased risk of congenital anomalies, particularly of the limbs and neural tube. Risk likely low but consider alternatives in first trimester. In second and third trimesters, no clear fetal toxicity but monitor for potential electrolyte imbalances and acidosis.
Dichlorphenamide is a carbonic anhydrase inhibitor. Data in pregnant women are insufficient. In animal studies, it has been associated with fetal skeletal abnormalities and reduced fetal weight at doses similar to human therapeutic doses. First trimester exposure may carry a risk of teratogenicity; second and third trimester risks include possible metabolic acidosis and electrolyte disturbances in the fetus.
Acetazolamide excreted into breast milk; M/P ratio approximately 0.25 for total acetazolamide, but for free drug may be higher. Milk levels low (about 10% of maternal serum). No reported adverse effects in infants; caution in neonates with renal or hepatic impairment, or those at risk for electrolyte disturbances.
It is not known whether dichlorphenamide is excreted in human breast milk. The M/P ratio is unknown. Due to the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug.
Pregnancy-induced pharmacokinetic changes (increased renal clearance, expanded plasma volume) may require dose adjustments. No specific guidelines; monitor clinical response and serum electrolyte levels. Consider starting at lower doses (e.g., 250 mg daily) and titrate based on response and tolerability. In severe conditions (e.g., glaucoma), maintain effective dose but monitor closely for electrolyte disturbances and metabolic acidosis.
No specific dose adjustments for pregnancy are established. However, due to pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance), careful monitoring of drug effect and tolerability is recommended. Dose may need individualized titration.
DIAMOX (acetazolamide) is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and edema. It can cause metabolic acidosis; monitor electrolytes. Avoid in severe hepatic or renal impairment. Use with caution in patients with sulfonamide allergy.
Dichlorphenamide is a carbonic anhydrase inhibitor used for primary open-angle glaucoma and familial periodic paralysis. Monitor serum potassium and perform baseline/periodic blood counts due to risk of hypokalemia and bone marrow suppression. Contraindicated in hepatic cirrhosis due to risk of hepatic encephalopathy. Can cause metabolic acidosis; use cautiously in patients with respiratory acidosis or COPD. Dose adjustment required in renal impairment. May increase urate levels; avoid in gout unless urate-lowering therapy is used.
Take exactly as prescribed; do not skip doses.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Drink plenty of fluids to prevent kidney stones.,Avoid alcohol as it may increase side effects.,Report any signs of allergic reaction (rash, hives, difficulty breathing) immediately.
Take exactly as prescribed; do not skip doses to prevent glaucoma progression.,Report any signs of bleeding, bruising, fever, or sore throat immediately.,May cause drowsiness; avoid driving or operating heavy machinery until effects known.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol and aspirin-containing products to reduce risk of metabolic acidosis.,Drink plenty of fluids to prevent kidney stones; maintain adequate hydration.,Notify doctor if you have liver disease, kidney stones, or breathing problems.,This may increase blood sugar; monitor if diabetic.,Taste disturbances or altered sense of taste may occur and are usually reversible.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIAMOX vs DICHLORPHENAMIDE, answered by our medical review team.
DIAMOX is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.. DICHLORPHENAMIDE is a Carbonic Anhydrase Inhibitor that works by Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIAMOX and DICHLORPHENAMIDE depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIAMOX is: 250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure. The standard adult dose of DICHLORPHENAMIDE is: 25-50 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIAMOX and DICHLORPHENAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIAMOX is classified as Category C. Diamox (acetazolamide) is a carbonic anhydrase inhibitor. Animal studies show teratogenic effects (limb malformations) at high doses, but human data limited. First trimester exposu. DICHLORPHENAMIDE is classified as Category C. Dichlorphenamide is a carbonic anhydrase inhibitor. Data in pregnant women are insufficient. In animal studies, it has been associated with fetal skeletal abnormalities and reduced. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.